Trials / Unknown
UnknownNCT04832776
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab | one group plus cetuximab |
| DRUG | Bevacizumab | one group plus bevacizumab |
| DRUG | FOLFOXIRI | FOLFOXIRI |
Timeline
- Start date
- 2021-04-17
- Primary completion
- 2023-12-31
- Completion
- 2025-12-31
- First posted
- 2021-04-06
- Last updated
- 2021-04-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04832776. Inclusion in this directory is not an endorsement.